2137 — Brii Biosciences Share News
0.000.00%
Last trade - 00:00- HK$645.88m
- -HK$1.49bn
- CNY18.61m
Brief: Brii Biosciences Says China's NMPA Granted Approval Of Co's Monoclonal Neutralizing Antibody Therapy
China approves Brii COVID treatment in adults, teenagers (updated)
China approves Brii Biosciences' COVID-19 treatment
China's Brii Biosciences jumps, says will up investment on COVID-19 virus therapy
Brief: Brii Biosciences Commits Additional Investment Of US$100 Mln For Investigational SARS-COV-2
Brief: Brii Biosciences Adds US$100 Million To Advance Its Late-Stage Monoclonal Antibody Combination Therapy, Brii-196/Brii-198, For Non-Hospitalized Covid-19 Patients
Brief: Brii Biosciences Posts HY Loss Attributable RMB 2.95 BLN
Brief: Brii Biosciences Says SARS-CoV-2 Neutralizing Monoclonal Antibody Combination Therapy Demonstrated Statistically Reduction Of 78%
Brief: Ma Yun's Long Position In Brii Biosciences At 7.58% - HKEx Filing
Brief: Brii Biosciences Says Its Majority-Owned JV Began Phase 2 Clinical Trial For Covid-19 Neutralizing Antibodies